Infiltrating immune cell proportions predict anti-tnf response in colon biopsies
AssigneesTechnion Research & Development Foundation Limited, The Board of Trustees of the Leland Stanford Junior University
InventorsShai S. SHEN-ORR, Elina STAROVETSKY, Naama MAIMON, Purvesh KHATRI, Renaud GAUJOUX, Francesco VALLANIA
Life of this patent
Estimating the term…
Abstract
Provided are methods of predicting responsiveness of a subject having an inflammatory bowel disease (IBD) to a tumor necrosis factor (TNF)-alpha inhibitor, by analyzing a frequency of at least one subpopulation of immune cells in a tissue biopsy of the subject. Also provided are methods of selecting a treatment for a subject and kits for determining responsiveness of the subject to treatment with a TNF-alpha inhibitor.
Claims29
A method of predicting responsiveness of a subject having an inflammatory bowel disease (IBD) to a tumor necrosis factor (TNF)-alpha inhibitor, comprising:
- analyzing a frequency of at least one subpopulation of immune cells in a tissue biopsy of the subject,
- wherein a frequency above a predetermined threshold of immune cells of a subpopulation selected from the group consisting of activated monocytes M1 macrophages, memory B cells, and neutrophils is indicative of the subject being non-responder to the TNF-alpha inhibitor, and/or
- wherein a frequency below a predetermined threshold of immune cells of a subpopulation selected from the group consisting of activated monocytes M2 macrophages and CD8+ T cells is indicative of the subject being non-responder to the TNF-alpha inhibitor,
- thereby predicting the responsiveness of the subject having the inflammatory bowel disease (IBD) to the TNF-alpha inhibitor.
3-6. (canceled)
8-9. (canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A kit for predicting responsiveness of a subject to a tumor necrosis factor (TNF)-alpha inhibitor comprising an agent capable of analyzing a frequency of at least one subpopulation of immune cells in a tissue biopsy of the subject, and a reference expression data of said frequency of at least one subpopulation of immune cells of a tissue biopsy obtained from at least one TNF-alpha inhibitor responder subject and/or at least one TNF-alpha inhibitor non-responder subject, wherein said immune cells are of a subpopulation selected from the group consisting of:
- activated monocytes M1 macrophages, memory B cells, neutrophils, activated monocytes M2 macrophages and CD8+ T cells.
27-28. (canceled)
Dependencies are inferred from the claim text.